PPD Development, L.P.
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- United States
- Registered address
- 8551 Research Way, Suite 90, Middleton, Wisconsin (WI) 53562, United States (USA)
- Operations here
- analysis
- FDA identifiers
- FEI 2129896 · DUNS 838082055
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- NAIBlood and Blood Products2026-05-01
- NAIHuman Cellular, Tissue, and Gene Therapies2026-05-01
- VAIDrug Quality Assurance2025-09-25
- VAIHuman Cellular, Tissue, and Gene Therapies2021-07-16
- NAIDrug Quality Assurance2019-09-19
- VAIBioresearch Monitoring2018-05-18
- NAIDrug Quality Assurance2013-11-20
- NAIDrug Quality Assurance2011-11-09
- NAIDrug Quality Assurance2009-07-24
Drugs this plant is listed as making
13 distinct drugs across 24 products name this site in their FDA label.
- buprenorphine hydrochloride, naloxone hydrochlorideIndivior Inc.
- elranatamab-bcmmPfizer Laboratories Div Pfizer Inc
- epinephrineAmneal Pharmaceuticals of New York LLC
- Manganese ChlorideHospira, Inc.
- methotrexatein shortageAntares Pharma, Inc.
- metoclopramideHospira, Inc.
- MotixafortideGamida Cell Inc.
- oritavancinMelinta Therapeutics, LLC
- oritavancin diphosphateMelinta Therapeutics, LLC
- tapinarofOrganon LLC
- tovorafenibDay One Biopharmaceuticals, Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.